Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

COVID-19 Clinical Trial

Official title:

A Phase I/II Single-Blinded Randomized Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of COVID 19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04684446
• Other study ID #: D8111C00003
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 15, 2021
• Est. completion date: March 29, 2022

Study information

• Verified date: June 2022
• Source: R-Pharm
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective is to evaluate the safety and immunogenicity of AZD1222 given in combination with (either before or after) rAd26-S, for the prevention of COVID 19 in adults ≥ 18 years of age.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: March 29, 2022
• Est. primary completion date: November 26, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 130 Years

Eligibility

Inclusion Criteria:

1. Adults = 18 years of age at the time of signing the informed consent

2. Overtly healthy as determined by medical evaluation, or

• Medically stable such that, according to the judgment of the investigator, hospitalisation within the study period is not anticipated and the participant appears likely to be able to remain in follow-up through the end of protocol-specified follow-up. o A stable medical condition is defined as disease not requiring significant change in therapy or hospitalisation for worsening disease during the 3 months prior to enrolment

3. Able to understand and comply with study requirements/procedures based on the assessment of the investigator

4. Reproduction:

Female participants

1. Women of childbearing potential must:

• Have a negative pregnancy test on the day of screening and on Day 1
• Use one highly effective form of birth control for at least 28 days prior to Day 1 and agree to continue using one highly effective form of birth control through 60 days following administration of the second dose of study vaccine. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly. Periodic abstinence, the rhythm method, and withdrawal are NOT acceptable methods of contraception.

2. Women are considered of childbearing potential unless they meet either of the

following criteria:

• Surgically sterilised (including bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or
• Postmenopausal

6. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: Medical Conditions

1. Known past laboratory-confirmed SARS-CoV-2 infection.

2. Positive SARS-CoV-2 RT PCR test at screening.

3. Seropositivity to SARS-CoV-2 at screening.

4. Significant infection or other illness, including fever > 37.8°C on the day prior to or on the day of randomization 5. Thrombocytopenia = Grade 2 (i.e. < 100 000/mm^3) 6. Clinically significant neutropenia (as determined by the investigator). 7. Clinically significant anaemia (as determined by the investigator) 8. Any confirmed or suspected immunosuppressive or immunodeficient state; including human immunodeficiency virus (HIV) infection; asplenia; recurrent severe infections and use of chronic immunosuppressant medication (within the past 6 months(= 20 mg/day of prednisone or its equivalent, given daily or on alternate days for = 15 days within 30 days prior to vaccination), except topical/inhaled steroids or short-term oral steroids ( course lasting = 14 days).

9. History of allergy to any component of the vaccine 10. Any history of anaphylaxis or angioedema. 11. Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and uterine cervical carcinoma in situ).

12. History of serious psychiatric condition likely to affect participation in the study.

13. Bleeding disorder (eg, factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture. 14 Suspected or known current alcohol or drug dependency. 15 History of Guillan-Barré syndrome or any other demyelinating condition. 16 Any other significant disease, disorder or finding which may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study or impair interpretation of the study data. 17 Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed).

18. Prior splenectomy 19. History of cerebral venous sinus thrombosis or experienced major venous and/or arterial thrombosis.

20. Receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination.

21. Prior or planned receipt of an investigational or licensed vaccine or product likely to impact on interpretation of the trial data (eg, adenovirus vectored vaccines, any coronavirus vaccines).

22. Administration of immunoglobulins and/or any blood products within the 3 months preceding the planned administration of the vaccine candidate.

23. Continuous use of anticoagulants, such as coumarins and related anticoagulants (ie, warfarin) or novel oral anticoagulants (ie, apixaban, rivaroxaban, dabigatran and edoxaban).

24. Participation in COVID-19 prophylactic drug trials for the duration of the study.

25. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

26. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

27. Previous randomisation in the present study 28. For female subjects only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding.

29. Unwilling to refrain from blood donation during the course of the study

Related Conditions & MeSH terms

• COVID-19

Intervention

Biological:
• AZD1222
Participants will receive 1 intramuscular (IM) injection of 5 ×1010 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×1011 viral particles (vp) (nominal) on Day 29 of the study
• rAd26-S
Participants will receive 1 IM injection of rAd26-S on Day 1 followed by AZD1222 on Day 29

Locations

Country	Name	City	State
Russian Federation	OJSC Clinical and Diagnostic Center Euromedservice	Moscow
Russian Federation	Federal State Budget Institution "Scientific and Research Institute of Flu n.a. A.A. Smorodintseva" of Ministry of Health of Russian Federation	Saint-Petersburg
Russian Federation	LLC PiterClinica	Saint-Petersburg
Russian Federation	Federal State Budgetary Educational Institution of Higher Education " First Saint Petersburg State Medical University named after Academician I. P. Pavlov" of the Ministry of Healthcare of the Russian Federation	St. Petersburg

Sponsors (4)

Lead Sponsor	Collaborator
R-Pharm	AstraZeneca, Russian Direct Investment Fund, The Gamaleya National Center of Epidemiology & Microbiology

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antibody seroconversion rate (= 4-fold increase from baseline) against SARS-CoV-2 neutralising antibodies 29 days post second vaccination.	Immunogenicity	Day 29 through Day 57
Primary	Incidence of local and systemic solicited AEs for 7 days following each vaccination (Day 1 through Day 7 for first vaccination and Day 29 through Day 35 for second vaccination).	Safety	Day 1 through Day 7 and Day 29 through Day 35
Primary	Incidence of unsolicited AEs, SAEs and AESIs through 29 days post each vaccination (ie, until Day 29 following the first vaccination and Day 57 following the second vaccination).	Safety	57 days
Secondary	Incidence of SAEs and AESIs after first vaccination until study end (Day 180).	Safety	180 days
Secondary	Antibody seroconversion rate (= 4-fold increase from baseline) against SARS-CoV-2 Spike protein	Immunogenicity	180 days
Secondary	Antibody seroconversion rate (= 4-fold increase from baseline) against RBD antigen.	Immunogenicity	180 days
Secondary	GMT and GMFR of immunogenicity against Spike and RBD antigens (MSD serology assay) at the day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180).	Immunogenicity	180 days
Secondary	Antibody seroconversion rate (= 4-fold increase from baseline) SARS-CoV-2 neutralising antibodies 29 days post first vaccination	Immunogenicity	Day 1 through Day 29
Secondary	GMT and GMFR of immunogenicity as measured by SARS-CoV-2 neutralising antibodies at day of vaccination (baseline), Day 15, 29 days post each vaccination and at study end (Day 180).	Immunogenicity	180 days
Secondary	Intracellular cytokine staining, including quantification of Th1/Th2 responses, and flow cytometry for B- and T-cell responses from day of dosing baseline to 29 days post each vaccination and until study end	Safety	180 days
Secondary	A binary response, whereby a participant is defined as a COVID-19 case if their illness (virologically confirmed [RT-PCR positive] and symptomatic) occurs	Efficacy	Day 29 through Day 180